N4 Pharma Plc

The Human Cell Atlas project aims to map all 37 trillion cells in the human body, with the potential to revolutionise our understanding of how the human body functions and diseases develop.   Amongst its latest discoveries the project has revealed a new cell form, the gut metaplastic cell, which is linked to exacerbating inflammation in individuals that live with inflammatory bowel diseases.   As scientific knowledge of human cells improves, treatments that can target specific cell types through technologies, such as Nuvec®, will become more in demand.   Read the article from BBC News to learn more about the exciting milestone findings from this innovative project which is enhancing scientists’ understanding of the human body: https://lnkd.in/eSCsXy23   #IBD #cell #disease

Join N4 Pharma Plc at Mello2024 for the 10th year of Mello Events' premier investor event at Derby Conference Centre. Our CEO Nigel Theobald will be speaking at the conference on Tuesday 19th November at 4:10pm in the Cavendish room and will present N4 Pharma's strategic focus on its two key lead programs: N4 101 for #IBD and ECP 105 for prevention of post-surgical scarring following #glaucoma treatment. If you haven't already got your tickets, visit: https://lnkd.in/eN-ypXWB

Join our growing shareholder community on the N4 Pharma Investor Hub! This month we released our updated corporate presentation alongside a video from CEO Nigel Theobald, and we've been engaging with our investor base through their questions on the hub. Sign up to get updated on N4 Pharma news and ask us anything! https://lnkd.in/eRNh6cC9

📢 Investor Q&A Session now LIVE – N4 Pharma Plc CEO Nigel Theobald recently addressed key investor questions following our latest corporate presentation: https://lnkd.in/eegWhpEc Nigel covers topics including: 1️⃣ Company Valuation: Why he believes N4 Pharma is undervalued and the potential market positioning. 2️⃣ Data Sharing and Updates: Plans for progress updates on N4 101 and other projects. 3️⃣ Collaboration Development: Insights into potential partnerships, especially after the SRI collaboration. 4️⃣ Orphan Drug Designation (ODD): Potential impact for ECP 105 if ODD isn’t granted. 5️⃣ Upcoming Milestones: What’s next for N4 Pharma and the expected market impact. Dive into the full Q&A to get the latest insights and stay informed on N4 Pharma’s journey. Submit any further questions here: https://lnkd.in/eegWhpEc

Our CEO Nigel Theobald shares his insight into 'the one thing that could dramatically improve the #pharma industry as we know it' with The Medicine Maker, emphasising the importance of government support and investment in small #biotech companies, which he believes could significantly enhance innovation and efficiency within the sector. Find out why, according to Nigel, "the traditional pharma model is no longer fit for purpose and needs a dramatic overhaul" here: https://lnkd.in/eFp9J_s3

We have developed a new corporate presentation outlining our strategic focus on N4 Pharma's two lead programs: N4 101 for Irritable Bowel Disease (IBD) and ECP 105 for post-surgical scarring prevention. Watch the video update from our CEO, Nigel Theobald here: https://lnkd.in/e-n7C7cb

Interesting to see Judo Bio raising funds to take forward its ligand-siRNA conjugates for delivering RNA-based medicines directly into specific cells of the kidney. Having secured $100 million in a combined seed and Series A financing, co-led by Atlas Venture, The Column Group and Droia Ventures, this move shows the value of targeted #siRNA products and their vast market potential. Read more: https://lnkd.in/eFCsjQJa

Tune in as our CEO, Nigel Theobald, joins Feliza Mirasol, Science Editor at MJH Life Sciences® to discuss the challenges of developing alternative delivery systems for #biologics on Pharmaceutical Technology’s Drug Solutions podcast Nigel shares his insights on biologics and biotherapeutics in the pharmaceutical industry, discusses what he believes will be the next big “breakthrough”, and offers his vision for the future of emerging #therapies. Listen to the podcast episode here: https://lnkd.in/enibSM2J

We are proud to announce the completion of the first stage of our project with SRI, an independent nonprofit research institute based in Silicon Valley.   Our CEO Nigel Theobald commented, "We have now shown that not only is Nuvec® capable of modification with a ligand to target specific cells, but also the combined new Nuvec® nanoparticle retains its ability to knockdown the target gene".    Now, both N4 Pharma and SRI will present the new data and implications to major pharma and biotech companies that need a targeting delivery system for their nucleic acid programs. Read the full update here: https://lnkd.in/ee9zZ4ia

Introducing N4 Pharma's new Non-Executive Director Dr Michael Palfreyman! With over four decades of experience guiding #biotechnology companies and foundations including Cybin Inc and NeurAegis, Inc., N4 Pharma Plc’s new NED Dr Palfreyman is co-inventor on 55 issued US and European patents, multiple pending patents, and has co-authored over 150 scientific articles and book chapters. Read more here: https://lnkd.in/eHqyWYs9